Revenue: As of FY2025, the actual value is USD 16.37 M.EPS: As of FY2025, the actual value is USD -0.13.EBIT: As of FY2025, the actual value is USD -6.895 M.<h4>Overall Financial Performance</h4>Net revenues for FOXO Technologies Inc. were $16,367,617 in 2025, a 303.98% increase from $4,051,601 in 2024.Total operating expenses increased by 125.99% to $26,696,831 in 2025 from $11,813,515 in 2024.Loss from operations increased by 33.08% to - $10,329,214 in 2025 from - $7,761,914 in 2024.Net loss attributable to FOXO Technologies Inc. was - $12,430,390 in 2025, a slight increase of 0.19% from - $12,406,389 in 2024.Cash used in operating activities was - $3,865,117 in 2025, compared to - $2,840,614 in 2024.<h4>Healthcare Segment</h4>Net revenues for the Healthcare segment were $16,086,099 in 2025, a 300% increase from $4,018,961 in 2024, including $3.5 million from the State of Tennessee’s Hospital Improvement Plan (THIP) in 2025.Operating expenses were - $25,010,019 in 2025, up from - $5,732,626 in 2024, which included a $7.0 million goodwill impairment in 2025.The segment loss increased to - $8,907,179 in 2025 from - $1,699,092 in 2024, primarily due to the goodwill impairment.<h4>Life Science Services Segment</h4>The Life Science Services segment, which commenced operations with the acquisition of Vector on September 19, 2025, generated net revenues of $252,502 in 2025.Operating expenses were - $370,994 in 2025.The segment reported a loss of - $118,492 in 2025.<h4>Labs Segment</h4>Net revenues for the Labs segment decreased by -57% to $13,923 in 2025 from $32,640 in 2024, primarily consisting of royalty income.Operating expenses decreased by -84% to - $187,306 in 2025 from - $1,173,945 in 2024, due to paused or discontinued research and development projects.The segment loss decreased by -85% to - $173,383 in 2025 from - $1,141,305 in 2024.<h4>Outlook / Guidance</h4>FOXO Technologies Inc. lacks sufficient cash to fund operations for the next twelve months and requires additional capital to execute its business strategy.The Healthcare segment plans to expand services and pursue acquisitions, while the Life Science Services segment aims for organic expansion and acquisitions.The Labs segment’s future depends on securing required capital to monetize and grow its epigenetics business, potentially through partnerships, joint ventures, or a sale.

FOXO TECHNOLOGIES INC | 10-K: FY2025 Revenue: USD 16.37 M